开发一种高亲和度的抗ROR1可变区域,用于广泛的抗癌免疫疗法.
Joshua K M Wong1, Pui Yeng Lam1, Elaina Coleborn1
1Frazer Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.
概括
研究人员开发了针对三阴性乳腺癌 (TNBC) 的新型疗法,这些疗法针对受体氨酸激酶类孤儿受体1 (ROR1). 将ROR1-向与TGF-β抑制相结合,增强了抗癌疗效和持久性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 受体氨酸激酶类孤儿受体1 (ROR1) 在侵袭性三阴性乳腺癌 (TNBC) 中高度表达.
- 目前的ROR1向疗法,如CAR T细胞,显示出希望,但面临有效性和毒性挑战.
- 基于自然杀手 (NK) 细胞的免疫疗法为癌症治疗提供了一个潜在的更安全的替代方案.
研究的目的:
- 开发针对TNBC的新型ROR1向免疫疗法.
- 评估针对ROR1的仿真单克隆抗体和CAR NK细胞对TNBC的疗效.
- 研究TGF-β抑制对ROR1向治疗的协同效应.
主要方法:
- 开发一种菌体衍生的单链碎片变量 (scFv),针对ROR1.1.
- 产生scFv衍生的仿真单克隆抗体和ROR1特异性的CAR NK细胞.
- 对TNBC细胞的抗癌疗效的评估和TGF-β抑制策略的评估.
主要成果:
- 开发的基于scFv的抗体和CAR NK细胞证明了对TNBC细胞的抗癌疗效.
- 针对ROR1的疗法在与TGF-β抑制相结合时显示出更好的持久性和有效性.
- 使用小分子抑制剂或CRISPR-Cas9编辑NK细胞实现了TGF-β抑制.
结论:
- 针对ROR1的新型免疫疗法,包括CAR NK细胞,对TNBC有效.
- 将ROR1向策略与TGF-β抑制相结合,可显著提高治疗结果.
- 这些发现支持开发用于TNBC治疗的基于ROR1的先进免疫疗法.
关键词:
ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC is also known as ADCC ADCC ADCC is also known as ADCC在CAR NK细胞中,这就是CRISPR/Cas9的作用.在Frizzled-Kringle域名中.在TGFBR2的淘汰赛中.抗体药物联合体的抗体.自然杀手细胞是自然杀手细胞.菌体显示器可以显示菌体.scFvv 在线阅读三重阴性乳腺癌是什么相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Vaccines
932
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
932
Rous Sarcoma Virus (RSV) and Cancer
6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.1K


